Nintedanib soft capsules 100 mg

Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection (MHRA release July 2020)

Before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors, carefully consider the risk of aneurysm and artery dissection in patients with risk factors. In patients who receive a systemic VEGF pathway inhibitor, reduce as far as possible any modifiable risk factors such as hypertension.

Further information can be found in the MHRA Drug Safety Update (https://www.gov.uk/drug-safety-update/systemically-administered-vegf-pathway-inhibitors-risk-of-aneurysm-and-artery-dissection#full-publication-update-history)